Novartis Radioligand Business Suffers Manufacturing Blow
Just Months After Pluvicto Approval
The Swiss major has hit pause on two manufacturing sites for its radioligands, Pluvicto and Lutathera, mere months after the former’s approval due to emerging quality concerns.
You may also be interested in...
Fewer Drug Launches In 2022, But Standouts Among Them
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.
Radioligands Advance Radiotherapy Premise With Greater Precision
With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer.
Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus
Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.